The IBS Program™ / The IBS Solution™ By Julissa Clay The IBS program comes in the format of a step-by-step program that can be purchased by anyone curious. The product is designed for everyone who wants to control their IBS symptoms and enjoy a pain-free life. One of the most impressive aspects of this program is that you may complete the workouts. You may do the workouts during the lunch hour, on a flight, or even at the house, and the great news is that you don’t need special equipment to complete them.
How does Rome IV prevalence compare with Rome III across continents, supported by survey harmonization studies, and how do cultural reporting differences affect estimates?
The prevalence of functional gastrointestinal disorders (FGIDs) under the Rome IV criteria is significantly lower across all continents compared to the older Rome III criteria. This reduction is a direct result of the stricter diagnostic requirements introduced in Rome IV. Cultural reporting differences also play a crucial role, as variations in how people perceive and express symptoms like pain can significantly affect survey-based prevalence estimates, making direct cross-continental comparisons challenging.
📜 From Rome III to Rome IV: A Stricter Definition
The Rome criteria are a set of diagnostic guidelines developed by international experts to classify functional gastrointestinal disorders (FGIDs), such as Irritable Bowel Syndrome (IBS), functional dyspepsia, and functional constipation. Over the years, these criteria have been updated to reflect an evolving understanding of these conditions. The shift from the Rome III criteria (published in 2006) to the Rome IV criteria (published in 2016) represented a major effort to make the definitions more specific and clinically relevant.
The most impactful change was for Irritable Bowel Syndrome (IBS). Under Rome III, the definition of pain was broad, described simply as “abdominal pain or discomfort.” The Rome IV criteria made this significantly stricter, requiring “recurrent abdominal pain.” The term “discomfort” was eliminated to remove ambiguity. Furthermore, Rome IV specified that the pain must be present, on average, at least one day per week in the last three months. The Rome III criteria had a less frequent requirement of at least three days per month. These changes were deliberately designed to increase the specificity of the diagnosis, identifying a more homogenous group of patients with a clearer and more burdensome symptom profile, while excluding those with milder or less frequent symptoms. The intended and actual consequence of these stricter rules was a worldwide reduction in the estimated prevalence of IBS.
📊 The Global Drop: Evidence from Harmonization Studies
The impact of this change in criteria was not theoretical; it has been clearly demonstrated in large, international epidemiological studies that have harmonized their survey methods across different continents. The most definitive evidence comes from the Rome Foundation Global Epidemiology Study. This monumental internet-based survey collected data from over 73,000 adults in 33 countries across North America, South America, Europe, Asia, and Australia, applying the exact same diagnostic questionnaire based on the Rome IV criteria.
The results of this study confirmed that the prevalence of all FGIDs, and particularly IBS, was lower under Rome IV than historical estimates from the Rome III era. Under Rome IV, the global prevalence of IBS was found to be approximately 4.1%. This stands in stark contrast to the prevalence estimates from the Rome III era, which typically ranged from 10% to 15% globally. This represents a more than 50% reduction in the estimated prevalence of the condition.
This drop was seen consistently across all continents. Whether in North America, Europe, or Asia, the application of the stricter Rome IV criteria resulted in a lower number of individuals meeting the threshold for an IBS diagnosis. These harmonization studies are critical because by using the same methodology everywhere, they confirm that the observed drop in prevalence is a true consequence of the change in diagnostic criteria, not just a random variation between different studies.
🗣️ The Cultural Lens: How Reporting Differences Affect Estimates
While harmonized surveys provide a clearer picture, a major challenge in comparing FGID prevalence across continents is the influence of cultural reporting differences. The diagnosis of FGIDs is based entirely on a patient’s subjective reporting of symptoms like pain, bloating, and discomfort. How an individual perceives, interprets, and communicates these internal experiences is deeply shaped by their cultural background, language, and societal norms.
For example, the concept and vocabulary used to describe “pain” can vary significantly. In some Western cultures, it is common to describe pain with a high degree of specificity and to seek medical care for it promptly. In some Eastern cultures, there may be a greater emphasis on stoicism, or the symptoms might be expressed in more holistic or somatic terms rather than as “pain.” These differences can directly impact how a person answers a standardized questionnaire.
Studies have shown that individuals in some regions, like parts of Latin America, may report a higher overall symptom burden, which could lead to higher prevalence estimates. Conversely, individuals in some Asian countries might report a lower burden, even with similar underlying physiology. Furthermore, the stigma associated with bowel symptoms can vary. In some cultures, discussing constipation or diarrhea is highly taboo, which could lead to underreporting. These cultural factors act as a “filter” through which the diagnostic criteria are applied, and they can create apparent differences in prevalence that may not reflect true differences in the underlying biology of the disease. This is why, even with the harmonized Rome IV data, experts are cautious about making direct “country vs. country” comparisons without considering the profound impact of culture on symptom reporting.
Product Name : The IBS Program™ / The IBS Solution™
Author/Creator: Julissa Clay
Normal price was $149. But now you can buy it at $149 $49 (100$ OFF)
I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more |